Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China flag China · Delayed Price · Currency is CNY
46.07
-1.25 (-2.64%)
Aug 31, 2026, 3:00 PM CST

SHA:600276 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
7,7227,7116,3374,3023,9064,530
Depreciation & Amortization
927.68843.38776.03704.64577.89520.41
Other Amortization
88.5199.0994.7989.366.2620.33
Loss (Gain) From Sale of Assets
-42.37-4.05-5.4-3.16-5.47-3.37
Asset Writedown & Restructuring Costs
-647.1872.264.9476.21131.24-117.52
Loss (Gain) From Sale of Investments
-72-116.09-132.535.62-533.84-169.57
Provision & Write-off of Bad Debts
19.0219.02-28.67-15.7726.02-3.87
Other Operating Activities
1,116403.2330.8317.02-67.79-27.8
Change in Accounts Receivable
-1,171-1,097-375.72,036-2,285-868.27
Change in Inventory
-439.74-479.24-135.63129.11-52.68-631.22
Change in Accounts Payable
1,5464,135671.41315.32-511.05809.7
Change in Other Net Operating Assets
106.3953.02209.2655.4734.98253.16
Operating Cash Flow
8,92211,2357,4237,6441,2654,219
Operating Cash Flow Growth
2.66%51.36%-2.89%504.12%-70.01%22.93%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,272-2,962-1,969-1,484-1,992-1,665
Sale of Property, Plant & Equipment
67.7218.9121.920.1820.2116.11
Divestitures
----36.05-
Investment in Securities
-314.3151-17.22,5902,160842.49
Other Investing Activities
38.0651.4952.5195.51166.49259.77
Investing Cash Flow
-3,480-2,741-1,9121,222390.29-546.26

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
----1,260-
Long-Term Debt Issued
-1,496799.9121.1--
Total Debt Issued
2,9871,496799.9121.11,260-
Long-Term Debt Repaid
--1,544-847.28-1,315-36.28-31.05
Net Debt Issued (Repaid)
-50.31-48.23-47.38-1,2941,224-31.05
Issuance of Common Stock
418.1710,770----
Repurchase of Common Stock
-978.15-978.15-228.43-827.26-1,066-235.16
Common Dividends Paid
-1,338-1,284-1,275-1,023-1,016-1,066
Other Financing Activities
100.98-677.76--538.86334.14
Financing Cash Flow
-1,8487,782-1,551-3,144-318.77-998.32

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-1,105-360.137.412.5380.5-16.87
Net Cash Flow
2,48915,9163,9685,7341,4172,657

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
5,6508,2735,4546,160-726.912,554
Free Cash Flow Growth
-11.97%51.71%-11.47%---11.24%
Free Cash Flow Margin
18.04%26.16%19.49%26.99%-3.42%9.86%
Free Cash Flow Per Share
0.851.270.860.97-0.110.40
Levered Free Cash Flow
3,2755,8594,3914,866-2,0301,151
Unlevered Free Cash Flow
3,2845,8684,3944,869-2,0261,154

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
2,9692,7872,2901,5681,6311,607
Change in Working Capital
-189.872,207346.192,437-2,835-530.01